Shots: The approval is based on P-lll CASSIOPEIA (MMY3006) Study involve the assessing of Darzalex (daratumumab) + bortezomib, thalidomide, and dexamethasone (VTd) for the treatment of patients with multiple myeloma […]readmore
Tags : Health Canada Approval
Shots: The approval is based on P-lll COAST-X study assessing Taltz (80mg, q4w) vs PBO for the treatment of adult patients with nr-axSpA with objective signs of inflammation for 52wks. […]readmore
Shots: The approval is based on P-lll SUNBEAM & RADIANCE part B study which involves the assessing of Zeposia (0.92mg and 0.46 mg) vs Avonex (qw, IM) in 1,346 & […]readmore
Shots: The approval is based on the P-lll BELIEVE study assessing Reblozyl (luspatercept) + BSC vs PBO + BSC in adult patients with anemia associated with beta-thalassemia requiring regular RBC […]readmore
Shots: The approval is based on P-III C-AXSPAND study assessing Cimzia (400mg) vs PBO + common background medications in 317 patients with severe active nr-axSpA with an objective sign of […]readmore